Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immunocytochemistry and Immunohistochemistry01:22

Immunocytochemistry and Immunohistochemistry

12.1K
Immunocytochemistry (ICC) and immunohistochemistry (IHC) are techniques that use antibodies to check for specific proteins or antigens in a sample. The technique was first published by Albert Coons in 1941 to detect the presence of pneumococcal antigen in tissue sections from mice infected with Pneumococcus. Immunocytochemistry helps localization of proteins or antigens in individual cells like blood cells, stem cells, etc., while immunohistochemistry does the same for tissue samples.
These...
12.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma.

Blood advances·2026
Same author

Antimicrobial resistance profiles of ESKAPE pathogens isolated in a microbiology laboratory in Somalia: a two-year retrospective study.

BMC infectious diseases·2026
Same author

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026
Same author

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs.

Blood advances·2026
Same author

Deployment of AI-driven automated quality control of whole-slide images in a large tertiary cancer center.

Journal of pathology informatics·2026
Same author

Genomic features do not account for differences in multiple myeloma risk by ancestry.

Blood cancer discovery·2026

Related Experiment Video

Updated: Sep 25, 2025

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
10:49

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

20.9K

Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus.

Alejandro A Gru1, Megan S Lim2, Ahmet Dogan3

  • 1From the Department of Pathology, E. Couric Clinical Cancer Center, University of Virginia, Charlottesville (Gru).

Archives of Pathology & Laboratory Medicine
|April 26, 2022
PubMed
Summary

CD30 immunohistochemistry is crucial for diagnosing lymphomas like Hodgkin lymphoma and T-cell lymphomas. New guidelines recommend reporting any CD30 expression to aid treatment decisions and standardize practices.

More Related Videos

Standardized Processing for Formalin-Fixed, Paraffin-Embedded Cell Pellet Immunohistochemistry Controls
06:43

Standardized Processing for Formalin-Fixed, Paraffin-Embedded Cell Pellet Immunohistochemistry Controls

Published on: July 27, 2022

8.3K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.5K

Related Experiment Videos

Last Updated: Sep 25, 2025

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
10:49

Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens

Published on: January 21, 2019

20.9K
Standardized Processing for Formalin-Fixed, Paraffin-Embedded Cell Pellet Immunohistochemistry Controls
06:43

Standardized Processing for Formalin-Fixed, Paraffin-Embedded Cell Pellet Immunohistochemistry Controls

Published on: July 27, 2022

8.3K
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.5K

Area of Science:

  • Hematopathology
  • Oncology
  • Immunohistochemistry

Background:

  • CD30 testing is established for lymphoma diagnosis and emerging as a predictive biomarker.
  • Current CD30 positivity definitions are descriptive, lacking established thresholds, leading to inconsistencies.
  • Challenges include preanalytic variables, tissue processing, and interpretation variability.

Purpose of the Study:

  • To develop best practice recommendations for reporting CD30 expression by immunohistochemistry in lymphoma biopsies.
  • To harmonize practices across institutions for consistent CD30 assessment.
  • To facilitate the evaluation of CD30's significance in clinical decision-making.

Main Methods:

  • Literature review and expert group discussions involving hematopathologists and hematologist-oncologists.
  • Formation of working groups focused on CD30 testing, readout, and interpretation.
  • Review of panel recommendations and confirmation via an online survey.

Main Results:

  • CD30 immunohistochemistry is required for differential diagnosis of classic Hodgkin lymphoma and peripheral T-cell lymphomas.
  • Immunohistochemistry is the preferred methodology for CD30 testing.
  • Any degree of CD30 expression should be reported.

Conclusions:

  • Report CD30 expression for diagnostic purposes following established guidelines.
  • For therapeutic decisions, report the estimated percentage of positive tumor cells.
  • Descriptively report positive non-tumor cells when applicable.